A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

November 16, 2016

Study Completion Date

November 16, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

Ticagrelor

Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.

DRUG

Placebo

10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment

Trial Locations (20)

11562

Research Site, Cairo

11566

Research Site, Cairo

20817

Research Site, Bethesda

21131

Research Site, Alexandria

29425

Research Site, Charleston

33076

Research Site, Bordeaux

33079

Research Site, Mersin

33136

Research Site, Miami

37134

Research Site, Verona

40100

Research Site, Kisian

Research Site, Nairobi

65080

Research Site, Van

67091

Research Site, Strasbourg

00100

Research Site, Kikuyu

1107 2020

Research Site, Beirut

113-6044

Research Site, Beirut

01130

Research Site, Adana

HA1 3UJ

Research Site, Harrow

E1 1BB

Research Site, London

E9 6SR

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY